Total Payments
$5,010
2024 Payments
$414.35
Companies
37
Transactions
312
Medicare Patients
5,238
Medicare Billing
$666,445
Payment Breakdown by Category
Food & Beverage$4,894 (97.7%)
Education$116.37 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,894 | 308 | 97.7% |
| Education | $116.37 | 4 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $963.60 | 64 | $0 (2024) |
| Merck Sharp & Dohme LLC | $876.18 | 52 | $0 (2024) |
| ViiV Healthcare Company | $660.54 | 44 | $0 (2024) |
| Allergan, Inc. | $478.12 | 26 | $0 (2020) |
| Insmed, Inc. | $251.71 | 11 | $0 (2024) |
| Janssen Biotech, Inc. | $218.98 | 16 | $0 (2019) |
| Theravance Biopharma, Inc. | $179.02 | 14 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $171.48 | 15 | $0 (2019) |
| Theratechnologies Inc. | $149.76 | 10 | $0 (2020) |
| GlaxoSmithKline, LLC. | $137.16 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $414.35 | 19 | ViiV Healthcare Company ($101.19) |
| 2023 | $165.00 | 9 | Gilead Sciences, Inc. ($51.91) |
| 2022 | $59.62 | 4 | Gilead Sciences, Inc. ($29.79) |
| 2021 | $14.59 | 1 | AbbVie Inc. ($14.59) |
| 2020 | $268.37 | 19 | Gilead Sciences, Inc. ($88.52) |
| 2019 | $1,244 | 84 | Gilead Sciences, Inc. ($295.16) |
| 2018 | $1,174 | 85 | Gilead Sciences, Inc. ($249.38) |
| 2017 | $1,671 | 91 | Merck Sharp & Dohme Corporation ($427.61) |
All Payment Transactions
312 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Respiratory | ||||||
| 11/01/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: VACCINE | ||||||
| 08/22/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/20/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: VACCINES | ||||||
| 07/19/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: HIV | ||||||
| 07/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.72 | General |
| 06/11/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: HIV | ||||||
| 06/09/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/27/2024 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: Diabetes Care | ||||||
| 05/03/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: HIV | ||||||
| 04/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.90 | General |
| 04/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.52 | General |
| 03/28/2024 | Philips North America LLC | (9274) LLD (Device) | Food and Beverage | Cash or cash equivalent | $97.49 | General |
| Category: Medical Device | ||||||
| 03/26/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: HIV | ||||||
| 02/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.47 | General |
| 02/25/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/14/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: HIV | ||||||
| 01/22/2024 | Seqirus USA Inc | Fluad (Biological), Flucelvax | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Vaccines | ||||||
| 01/16/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: HIV | ||||||
| 12/19/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.34 | General |
| 12/16/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.39 | General |
| 11/06/2023 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO, DIFICID | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/27/2023 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO, DIFICID | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/26/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.18 | General |
| 09/22/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: HIV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,526 | 2,250 | $510,170 | $191,226 |
| 2022 | 18 | 1,328 | 2,018 | $446,060 | $161,187 |
| 2021 | 15 | 1,176 | 1,784 | $395,870 | $158,617 |
| 2020 | 18 | 1,208 | 1,900 | $404,805 | $155,415 |
Total Patients
5,238
Total Services
7,952
Medicare Billing
$666,445
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 297 | 719 | $115,040 | $48,467 | 42.1% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 212 | 233 | $85,045 | $35,858 | 42.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 144 | 159 | $70,755 | $23,620 | 33.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 251 | $60,240 | $16,723 | 27.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 52 | 52 | $20,540 | $14,691 | 71.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 64 | 98 | $22,540 | $9,989 | 44.3% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 68 | 69 | $19,665 | $7,856 | 39.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 121 | 121 | $47,795 | $7,283 | 15.2% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Facility | 2023 | 114 | 197 | $19,700 | $6,637 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 34 | $11,050 | $4,080 | 36.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 56 | $9,240 | $2,837 | 30.7% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 22 | 22 | $4,690 | $2,827 | 60.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 34 | 34 | $3,060 | $2,446 | 79.9% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 52 | 52 | $3,640 | $1,766 | 48.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 49 | 50 | $3,500 | $1,699 | 48.5% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 18 | 20 | $4,600 | $1,235 | 26.8% |
| 90682 | Influenza vaccine, quadrivalent derived from recombinant dna | Office | 2023 | 15 | 15 | $1,350 | $1,076 | 79.7% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 22 | 22 | $2,640 | $996.38 | 37.7% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 13 | 18 | $3,240 | $802.74 | 24.8% |
| 90471 | Administration of vaccine | Office | 2023 | 13 | 16 | $1,120 | $260.68 | 23.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 11 | 12 | $720.00 | $78.60 | 10.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 292 | 710 | $113,600 | $43,596 | 38.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 148 | 155 | $68,975 | $26,386 | 38.3% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 145 | 161 | $58,610 | $24,219 | 41.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 124 | 216 | $51,840 | $15,022 | 29.0% |
About Dr. Ashwin Jathavedam, MD
Dr. Ashwin Jathavedam, MD is a Infectious Disease healthcare provider based in Englewood, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1609862747.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashwin Jathavedam, MD has received a total of $5,010 in payments from pharmaceutical and medical device companies, with $414.35 received in 2024. These payments were reported across 312 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($4,894).
As a Medicare-enrolled provider, Jathavedam has provided services to 5,238 Medicare beneficiaries, totaling 7,952 services with total Medicare billing of $666,445. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine, Internal Medicine
- Location Englewood, NJ
- Active Since 09/23/2005
- Last Updated 02/02/2026
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1609862747
Products in Payments
- Arikayce (Drug) $251.71
- AVYCAZ (Drug) $231.95
- ISENTRESS (Drug) $200.50
- JULUCA (Drug) $193.12
- VIBATIV (Drug) $179.02
- TRIUMEQ (Drug) $161.09
- DIFICID (Drug) $159.57
- XARELTO (Drug) $154.39
- TEFLARO (Drug) $152.56
- ZERBAXA (Drug) $140.35
- PREZCOBIX (Drug) $135.34
- DALVANCE (Drug) $125.37
- DOVATO (Drug) $122.86
- NOXAFIL (Drug) $119.01
- SHINGRIX (Biological) $115.73
- JANUVIA (Drug) $107.25
- (9274) LLD (Device) $97.49
- EGRIFTA (Drug) $96.11
- APRETUDE (Biological) $84.18
- ELEVIEW (Device) $72.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Englewood
Dr. Suraj Saggar, D.o, D.O
Infectious Disease — Payments: $70,850
Infectious Disease $70,850
Sejal Gandhi, M.d, M.D
Infectious Disease — Payments: $1,020
Infectious Disease $1,020
Mihran Seferian, Md, MD
Infectious Disease — Payments: $773.27
Infectious Disease $773.27
Dr. James Knapp, Md, MD
Infectious Disease — Payments: $19.12
Infectious Disease $19.12